[Report] Urinary Incontinence Market Research, Trends, Analysis TOC

ABOUT DATAMONITOR HEALTHCARE
- About the Women' s Health pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
- Scope of the analysis
- Contributing experts
- Datamonitor insight into the urinary incontinence market
- Related reports
CHAPTER 2 MARKET OVERVIEW AND POTENTIAL
- Market and disease definition
  - Normal bladder function
  - Urinary Incontinence
  - Relationship between overactive bladder and UI
    - "Wet" overactive bladder is a form of urge UI
    - Dry overactive bladder can impact on quality of life
  - Definition of urinary incontinence market
- Market potential
  - Epidemiology of UI
    - Prevalence of UI
    - Prevalence high, but treatment rates are likely to be low
  - Stress urinary incontinence is the most common form of UI
  - Patient population with UI likely to rise with the ageing of the general population
  - Etiology of UI
    - Urge UI symptoms from overactive bladder
    - Stress urinary incontinence
    - Mixed urinary incontinence
  - Unmet need in UI
    - Efficacy in controlling symptoms
    - Reduction of side-effect profile
    - Alternative delivery mechanism
    - Reduced pill burden
    - Alternative targets
    - Stress urinary incontinence
- Current treatment classes and mechanisms
  - Treatment algorithm
    - Behavioral techniques
    - Pharmacological treatment
    - Medical devices
    - Surgery
- Current market value and future market forecasts
  - Current market dynamics
    - Anticholinergics dominate current market
    - The US generated more revenue from UI therapies than the EU and Japan combined
  - The UI market is set to grow throughout the forecast period
    - Near-term growth-reformulations
    - Medium-term growth-life-cycle management strategies, novel products and new markets
    - Long-term outlook-patent expiries take their toll
CHAPTER 3 BRAND DYNAMICS AND LEADING COMPARATOR THERAPIES
- Marketed brands overview
- Detrol (LA) (tolterodine)
  - Drug overview
  - Forecasts to 2016
  - SWOT analysis
  - Clinical trial data
    - Detrol' s clinical trial program and study designs
    - Efficacy of Detrol
    - Detrol side effects
    - Detrol drug-drug interactions
  - Mechanism of action
- Ditropan (oxybutynin/oxybutynin chloride)
  - Ditropan drug overview
  - Ditropan extended release
  - Forecasts to 2016
  - SWOT analysis
  - Clinical trial data
    - Ditropan' s clinical program and study designs
    - Efficacy of Ditropan XL
    - Ditropan XL side effects
- Oxytrol/Kentera (oxybutynin transdermal patch)
  - Drug overview
  - Forecasts to 2016
  - SWOT analysis
  - Clinical trial data
    - Oxytrol clinical program and study designs
    - Efficacy of Oxytrol
    - Side effects of Oxytrol
  - Mechanism of action
- Sanctura (trospium chloride)
  - Drug overview
  - Forecasts to 2016
  - Clinical trial data
    - Sanctura clinical program and study designs
    - Efficacy of Sanctura
    - Side effects of Sanctura
  - Mechanism of action
- Vesicare (solifenacin succinate)
  - Drug overview
  - Forecasts to 2016
  - SWOT analysis
  - Clinical trial data
    - Vesicare' s clinical trial program and study designs
    - Efficacy of Vesicare
    - Side effects of Vesicare
  - Mechanism of action
- Enablex (Darifenacin)
  - Drug overview
  - Forecasts to 2016
  - SWOT analysis
  - Clinical trial data
    - Enablex' s clinical trial program and study designs
    - Efficacy of Enablex
    - Side effects of Enablex
- Yentreve (duloxetine)
  - Drug overview
  - Forecasts to 2016
  - Clinical trial data
    - Efficacy and side effect profile observed in clinical trial program
- Mictonorm/Detrunorm/BUP-4 (propiverine)
  - Drug overview
  - Forecasts to 2016
  - Clinical trial data
    - Efficacy
    - Side-effect profile
    - Drug-drug interactions
- Hormone therapy (Estradiol)
- Others
CHAPTER 4 FORECAST ANALYSIS
- Key events
  - New product launches
    - Key drug launch assumptions
  - Product launches in Japan
    - Darifenacin (Enablex)
    - Imidafenacin (ONO-8025) (KRP-197) (Staybla/Uritos)
  - Reformulations
    - Detrol LA, Toviaz
    - Sanctura, Sanctura XR
    - Oxybutynin
  - Patent expiries
    - Sanctura
    - Detrol LA
    - Yentreve
    - Raft of patent expires in 2015
- Data definitions, limitations and assumptions
  - Standard units
  - Japanese market data
  - Derivation of sales forecasts and pricing trends
- Forecast methodology
CHAPTER 5 GLOBAL OPPORTUNITIES AND THREATS
- Key opportunities
  - Stress urinary incontinence
  - Room for a non-anticholinergic treatment
  - Niche topical market
  - Increased awareness
  - Elderly population
- Key threats
  - Generic anticholinergics
  - Behavioral/surgical techniques
  - Anticholinergic brands dominant
CHAPTER 6 PIPELINE OVERVIEW - R&D DYNAMICS AND APPROACH
- Pipeline overview
- Classification of pipeline products
  - Cholinergics
  - Adrenergic drugs
  - NK-1 modulators
  - Other drug classes
- Clinical trial design
  - Clinical trial endpoints in UI
  - Subjective outcome measures
  - Quantification of symptoms
    - Diaries
    - Pad weighing tests
    - Quality of life
    - Choice of endpoints
    - Specific safety aspects
CHAPTER 7 LATE-STAGE DRUG ANALYSIS & FORECASTS
- Late-stage pipeline overview
- Cholinergic class pipeline drugs
  - Pipeline summary
  - Sanctura XR
    - Drug overview
    - Forecasts to 2016
    - Marketing factors
    - Patient potential
    - Satisfaction of unmet needs
    - Clinical trial data
  - Toviaz (fesoterodine)
    - Drug overview
    - Forecasts to 2016
    - Marketing factors
    - Patient potential
    - Satisfaction of unmet needs
    - Clinical trial data
  - Oxybutynin transdermal gel
    - Drug overview
    - Antares Pharma' s oxybutynin gel
    - Watson Pharmaceuticals' oxybutynin gel
    - Forecasts to 2016
    - Marketing factors
    - Patient potential
    - Satisfaction of unmet needs
    - Oxybutynin TVR
  - Botox
    - Drug overview
    - Forecasts to 2016
    - Marketing factors
    - Patient potential
    - Satisfaction of unmet needs
    - Clinical trial data
  - SVT-40776
- Adrenergic class pipeline drugs
  - Pipeline summary
  - YM-178
    - Drug overview:
    - Forecasts to 2016
    - Clinical trial data
  - PSD-503
  - MN-246
- NK-1 modulator class pipeline drugs
  - Pipeline summary
  - NK-1 antagonist-theoretical clinical profile and forecast
    - Forecasts to 2016
    - Patient potential
    - Satisfaction of unmet needs
  - Casopitant (Rezonic)
  - SSR-240600
  - TA-5538
- Other pipeline drugs
  - Pipeline summary
  - VD3 analog (Elocalcitol)
    - Drug overview
    - Forecasts to 2016
    - Marketing factors
    - Patient potential
    - Unmet needs
    - Clinical trial data
  - RCD-1
  - FP-1097
  - URG-101
  - MK-0634
  - FE-106483
  - F-2695
- Recently suspended/discontinued drugs
  - Cizolirtine
  - (+)-(S,S) Reboxetine
  - REC-0545
  - Saredutant
  - KW-7158
  - KUC-7483
CHAPTER 8 EARLY-STAGE PROJECTS
- Key Phase I and earlier compounds in development for UI
  - Phase I overview
  - Stem cell therapy for SUI
  - Vanilloid agents
BIBLIOGRAPHY
- Journal papers
- Websites
- DM reports
APPENDIX
- Report methodology
  - Contributing experts
- About Datamonitor
  - About Datamonitor Healthcare
  - About the Women' s Health and Urology analysis team
  - Disclaimer
- List of Tables
  - Table 1: Definitions of UUI, SUI and MUI, according to the ICS
  - Table 2: Prevalence of UI across the seven major markets, 2007
  - Table 3: Detrol/Detrol LA: key facts
  - Table 4: Confidence intervals for the difference between Detrol and placebo
  - Table 5: Confidence intervals for the difference between Detrol LA and placebo
  - Table 6: Ditropan/Ditropan XL: key facts
  - Table 7: Oxytrol: key facts
  - Table 8: Sanctura: key facts
  - Table 9: Vesicare: key facts
  - Table 10: Enablex: key facts
  - Table 11: Yentreve: key facts
  - Table 12: Forecast launch dates in the US and 5EU
  - Table 13: Forecast launch dates in Japan
  - Table 14: Pivotal patent expiries for key marketed drugs in the US and 5EU
  - Table 15: Key pipeline drugs in late-stage development for UI, 2007
  - Table 16: Key late-stage development pipeline, cholinergic class, 2007
  - Table 17: Key factors impacting sales of Sanctura XR, 2007-16
  - Table 18: Key factors impacting sales of Toviaz, 2007-16
  - Table 19: Key factors impacting sales of oxybutynin gel, 2007-16
  - Table 20: Key factors impacting sales of Botox, 2007-16
  - Table 21: Key late-stage development pipeline, adrenergic class, 2007
  - Table 22: Key late-stage development pipeline, NK-1 modulator class, 2007
  - Table 23: Key late-stage development pipeline, other classes, 2007
  - Table 24: Key factors impacting sales of Elocalcitol, 2007-16
  - Table 25: Projects in Phase I and Preclinical development for UI, 2007
  - Table 26: Datamonitor drug assessment parameters
- List of Figures
  - Figure 1: Drug assessment summary overview of key marketed and pipeline urinary incontinence drugs, 2007
  - Figure 2: Historical (2003-06) and forecast (2007-16) UI sales revenue for key marketed and pipeline drugs across the 7MM
  - Figure 3: Relationship between UI and OAB
  - Figure 4: Female population suffering from each OAB/UI subtype
  - Figure 5: Female UI/OAB patients according to age group, across the seven major markets
  - Figure 6: Risks of specific side effects, according to interviewed physicians
  - Figure 7: UI-specific sales revenue, 7MM, 2003-06
  - Figure 8: UI-specific sales by revenue, by region and country, 2006
  - Figure 9: UI-specific sales by standard unit, by region and country, 2006
  - Figure 10: UI total market value in the US, Japan and 5EU, 2003-16
  - Figure 11: Current marketed drugs-clinical and commercial assessment
  - Figure 12: Sales (2006) and sales growth (2005-06) for key UI products
  - Figure 13: Detrol LA UI-specific sales revenue, 7MM, 2003-16
  - Figure 14: Detrol LA SWOT analysis
  - Figure 15: Ditropan XL UI-specific sales revenue, 7MM, 2003-16
  - Figure 16: Ditropan XL SWOT analysis
  - Figure 17: Oxytrol UI-specific sales revenue, 7MM, 2003-16
  - Figure 18: Oxytrol SWOT analysis
  - Figure 19: Sanctura UI-specific sales revenue, 7MM, 2003-16
  - Figure 20: Vesicare UI-specific sales revenue, 7MM, 2003-16
  - Figure 21: Vesicare SWOT analysis
  - Figure 22: Enablex UI-specific sales revenue, 7MM, 2003-16
  - Figure 23: Enablex SWOT analysis
  - Figure 24: Yentreve UI-specific sales revenue, 7MM, 2003-16
  - Figure 25: Mictonorm UI-specific sales revenue, 7MM, 2003-16
  - Figure 26: Impact of each key event on the UI market across the seven major markets, 2007-2016
  - Figure 27: SUI most prevalent indication
  - Figure 28: Generic UI sales, 7MM, 2003-16
  - Figure 29: Drugs in late-stage development by class, 2007+
  - Figure 30: Key late-stage pipeline overview, 2007
  - Figure 31: Forecast UI sales for Sanctura XR 7MM, 2007-16
  - Figure 32: Drug assessment summary for Sanctura XR, 2007
  - Figure 33: Forecast UI sales for Toviaz, 7MM, 2007-16
  - Figure 34: Drug assessment summary for Toviaz, 2007
  - Figure 35: Forecast UI sales for oxybutynin gel 7MM, 2007-16
  - Figure 36: Drug assessment summary for Oxybutynin gel, 2007
  - Figure 37: Forecast UI sales for Botox, 7MM, 2007-16
  - Figure 38: Drug assessment summary for Botox, 2007
  - Figure 39: Forecast UI sales for an NK-1 antagonist 7MM, 2007-16
  - Figure 40: Forecast UI sales for Elocalcitol 7MM, 2007-16
  - Figure 41: Drug assessment summary for Elocalcitol, 2007

Pipeline and Commercial Insight: Urinary Incontinence - Lifecycle management strategies retain mid-term market growth

Table of Contents